Literature DB >> 7688036

The pathogenesis of multiple sclerosis. Additional considerations.

C M Poser1.   

Abstract

Multiple sclerosis (MS) is acquired as a systemic "trait" by individuals who are genetically susceptible. This condition does not involve the central nervous system (CNS) and is characterized by a state of hyperactive immunocompetent responsiveness. It develops as the result of an antigenic challenge by a viral protein, either from a viral infection or a vaccination. In order for MS to become a disease affecting the CNS, it is necessary for the blood-brain barrier's (BBB) impermeability to be altered. This is now a fully recognized fact. As a result of this change, the MS lesion, which consists of edema and inflammation occurs. It may but need not lead to demyelination. Several mechanisms can cause this increased permeability of the BBB. The role of the immune system, and in particular of T lymphocytes in initiating and continuing the process of lesion formation remains extremely controversial. In fact, there are unanswered questions regarding the actual target of MS: is it the myelin sheath itself or its forming cell, the oligodendrocyte, or is it the BBB itself leading to bystander demyelination? The role of mild, concussional trauma to the CNS in producing the alteration of the BBB and therefore acting as a trigger or facilitator in the development or enlargement of MS lesions in the CNS, is based on considerable clinical, neuropathological and experimental evidence. Along with another viral infection, it must be one of the commonest causes of progression of MS, and quite often leads to the onset of the clinical manifestations of an hitherto asymptomatic condition.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7688036      PMCID: PMC7130122          DOI: 10.1016/0022-510x(93)90203-b

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  85 in total

1.  Blood-brain barrier damage in acute multiple sclerosis plaques. An immunocytological study.

Authors:  D Gay; M Esiri
Journal:  Brain       Date:  1991-02       Impact factor: 13.501

2.  Virus antibody titers in multiple sclerosis patients, siblings, and controls.

Authors:  J A Brody; J L Sever; T E Henson
Journal:  JAMA       Date:  1971-05-31       Impact factor: 56.272

3.  Induced localization of allergic adrenalitis and encephalomyelitis at sites of thermal injury.

Authors:  S Levine; E M Hoenig
Journal:  J Immunol       Date:  1968-06       Impact factor: 5.422

4.  Neuroparalytic accidents of antirabies vaccination with suckling mouse brain vaccine. Clinical and pathologic study of 21 cases.

Authors:  G Toro; I Vergara; G Román
Journal:  Arch Neurol       Date:  1977-11

5.  Autoreactive T lymphocytes in multiple sclerosis determined by antigen-induced secretion of interferon-gamma.

Authors:  T Olsson; W W Zhi; B Höjeberg; V Kostulas; Y P Jiang; G Anderson; H P Ekre; H Link
Journal:  J Clin Invest       Date:  1990-09       Impact factor: 14.808

6.  Ultrastructural blood-brain barrier alterations and edema formation in acute spinal cord trauma.

Authors:  J H Goodman; W G Bingham; W E Hunt
Journal:  J Neurosurg       Date:  1976-04       Impact factor: 5.115

7.  Similar levels of immune complexes in cases of multiple sclerosis and their unaffected relatives.

Authors:  R W Haile; L M Karavodin; B R Visscher; R Detels; N L Valdiviezo
Journal:  J Neuroimmunol       Date:  1981-06       Impact factor: 3.478

8.  The epidemiology of multiple sclerosis: the Iceland model. Onset-adjusted prevalence rate and other methodological considerations.

Authors:  C M Poser; J Benedikz; P L Hibberd
Journal:  J Neurol Sci       Date:  1992-09       Impact factor: 3.181

9.  Molecular mimicry in virus infection: crossreaction of measles virus phosphoprotein or of herpes simplex virus protein with human intermediate filaments.

Authors:  R S Fujinami; M B Oldstone; Z Wroblewska; M E Frankel; H Koprowski
Journal:  Proc Natl Acad Sci U S A       Date:  1983-04       Impact factor: 11.205

10.  Human immunodeficiency virus in brain biopsies of patients with AIDS and progressive encephalopathy.

Authors:  F Gyorkey; J L Melnick; P Gyorkey
Journal:  J Infect Dis       Date:  1987-05       Impact factor: 5.226

View more
  7 in total

1.  Breakdown of the blood-retinal barrier induced by activated T cells of nonneural specificity.

Authors:  P Hu; J D Pollard; T Chan-Ling
Journal:  Am J Pathol       Date:  2000-04       Impact factor: 4.307

Review 2.  Oligodendroglial response to the immune cytokine interferon gamma.

Authors:  B Popko; K D Baerwald
Journal:  Neurochem Res       Date:  1999-02       Impact factor: 3.996

Review 3.  Aging, neurodegenerative disease, and traumatic brain injury: the role of neuroimaging.

Authors:  Carrie Esopenko; Brian Levine
Journal:  J Neurotrauma       Date:  2014-12-29       Impact factor: 5.269

4.  Urinary dysfunction in women with multiple sclerosis: analysis of 61 patients from rio de janeiro, Brazil.

Authors:  Camila Rodrigues de Almeida; Kennedy Carneiro; Rossano Fiorelli; Marco Orsini; Regina Maria Papais Alvarenga
Journal:  Neurol Int       Date:  2013-11-11

Review 5.  Herpesviruses--a rationale for antiviral treatment in multiple sclerosis.

Authors:  T Bergström
Journal:  Antiviral Res       Date:  1999-02       Impact factor: 5.970

Review 6.  The effects of interferon-gamma on the central nervous system.

Authors:  B Popko; J G Corbin; K D Baerwald; J Dupree; A M Garcia
Journal:  Mol Neurobiol       Date:  1997 Feb-Apr       Impact factor: 5.590

Review 7.  Two models of multiple sclerosis: experimental allergic encephalomyelitis (EAE) and Theiler's murine encephalomyelitis virus (TMEV) infection. A pathological and immunological comparison.

Authors:  M C Dal Canto; R W Melvold; B S Kim; S D Miller
Journal:  Microsc Res Tech       Date:  1995-10-15       Impact factor: 2.769

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.